| 石旦,李晓杰.霍奇金淋巴瘤免疫检查点及其抑制剂研究进展.[J].中南医学科学杂志.,2021,(2):244-248. |
| 霍奇金淋巴瘤免疫检查点及其抑制剂研究进展 |
| Research progress of immune checkpoints and inhibitor of Hodgkin lymphoma |
| |
| DOI：10.15972/j.cnki.43-1509/r.2021.02.026 |
| 中文关键词: 霍奇金淋巴瘤 免疫检查点 免疫检查点抑制剂 [ |
| 英文关键词:Hodgkin lymphoma immune checkpoint immune checkpoint inhibitor |
| 基金项目: |
|
| 摘要点击次数: 360 |
| 全文下载次数: 467 |
| 中文摘要: |
| 霍奇金淋巴瘤(HL)的预后较好,但仍有部分复发/难治性霍奇金淋巴瘤(R/RHL)患者是治疗的难点。近年来,程序性死亡受体1(PD-1)抑制剂的应用极大改善了其预后,但仍有部分患者初治无反应或复发,而这部分患者可能从新的免疫检查点抑制剂(ICIs)中获益。本文回顾了近年来新发现的免疫检查点(IC)及其抑制剂,并对其研究进展进行综述,探讨其作为霍奇金淋巴瘤治疗靶向点的可能性,旨在为临床治疗提供新的思路。 |
| 英文摘要: |
| Hodgkin's lymphoma (HL) has a good prognosis, but it is still difficult to treat some patients with relapsed/refractory Hodgkin's lymphoma (R/RHL). In recent years, the application of programmed cell death receptor 1(PD-1) inhibitors has greatly improved the prognosis, but some patients still have no response or relapse after initial treatment, and these patients may benefit from new immune checkpoint inhibitors (ICIs). This paper reviewed the newly discovered immune checkpoint (IC) and its inhibitors in recent years, and summarized their research progress, exploring their possibility as treatment targeting points for Hodgkin's lymphoma, in order to provide new ideas for clinical treatment. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|